DBV Technologies | DBVT - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Alnylam Pharmaceuticals USD 179.66M 67.06M 2026-09
Amarin USD -2.26M 564K 2025-12
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
DBV Technologies USD -64.8M 16.9M 2026-09
Galectin Therapeutics USD -11.29M 1.64M 2024-06
Halozyme Therapeutics USD -63.72M 1.95M 2026-06
Incyte USD -707.47M 1.41B 2026-09
Insmed USD -81.83M 19.48M 2026-09
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Neurocrine Biosciences USD 343M 123.1M 2026-09
PTC Therapeutics USD 148.98M 103.09M 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
United Therapeutics USD 330.8M 5M 2026-06